Incyte Corporation (0J9P.L)
| Previous close | 51.71 |
| Open | 52.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 52.10 - 53.88 |
| 52-week range | 50.81 - 75.42 |
| Volume | |
| Avg. volume | 2,831 |
| Market cap | 117.089M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Incyte First […]
- Zacks
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
- Reuters
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.
